Oncogenic osteomalacia

A disorder that occurs with certain types of tumors, such as connective tissue tumors or OSTEOBLASTOMA, that secrete fibroblast growth factor 23. This causes reduced renal phosphate reabsorption and poor bone mineralization, resulting in bone fractures, bone pain, and muscle weakness.

Also Known As:

Networked: 420 relevant articles (8 outcomes, 19 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Paraneoplastic Syndromes (Paraneoplastic Syndrome)
3.	Familial Hypophosphatemic Rickets (X-Linked Hypophosphatemia)
4.	Hypophosphatemia
5.	Hypophosphatemic Rickets

Experts

1.	Fukumoto, Seiji: 17 articles (01/2022 - 07/2002)
2.	Collins, Michael T: 14 articles (12/2021 - 09/2003)
3.	Li, Fang: 7 articles (02/2022 - 08/2013)
4.	Kumar, Rajiv: 7 articles (12/2021 - 06/2002)
5.	Folpe, Andrew L: 7 articles (06/2021 - 01/2004)
6.	Jüppner, Harald: 7 articles (03/2013 - 02/2003)
7.	Econs, Michael J: 7 articles (12/2009 - 04/2003)
8.	White, Kenneth E: 7 articles (09/2009 - 04/2003)
9.	Ito, Nobuaki: 6 articles (01/2022 - 01/2017)
10.	Imanishi, Yasuo: 6 articles (01/2021 - 04/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Oncogenic osteomalacia:

1.	Phosphates (Orthophosphate)IBA 06/01/2019 - "The patient's symptoms improved rapidly, and the serum phosphate normalized after surgery, which supports the diagnosis of tumor-induced osteomalacia. " 07/01/2023 - "Thermal Ablation for Treating Tumor-induced Osteomalacia in a Patient With IV Phosphate Dependency." 06/01/2016 - "It is associated with paraneoplastic oncogenic osteomalacia through secretion of fibroblast growth factor-23 (FGF-23) which inhibits renal proximal tubule phosphate re-uptake. " 08/01/2009 - "Renal phosphate wasting due to tumor-induced osteomalacia: a frequently delayed diagnosis." 10/01/2005 - "In these cases, the pathophysiology of the phosphate renal wasting notably differs from oncogenic osteomalacia and is due to light-chain nephropathy, resulting in proximal tubular dysfunction which is not restricted to phosphate handling. "
2.	Fibroblast Growth Factor-23IBA 09/01/2022 - "Phosphaturic mesenchymal tumour (PMT) is a rare tumour that occurs in bone or soft tissue and is associated with production of fibroblast growth factor 23 (FGF23) leading to tumor-induced osteomalacia. " 01/01/2022 - "Tumor-induced osteomalacia (TIO) is a rare paraneoplastic disorder caused by excessive fibroblast growth factor 23 (FGF23) secretion. " 01/01/2021 - "When the positive PHEX mutation and very high fibroblast growth factor 23 level were detected, PET-CT imaging was performed with a pre-diagnosis of possible oncogenic osteomalacia, but no finding was found. " 01/01/2018 - "Oncogenic osteomalacia is an endocrine disorder induced by small benign tumours (TIO) producing excessive fibroblast growth factor-23 (FGF23). " 09/01/2017 - "Localization of Oncogenic Osteomalacia by Systemic Venous Sampling of Fibroblast Growth Factor 23."
3.	Vitamin DFDA LinkGeneric 04/01/1985 - "Studies of vitamin D metabolism and renal tubular function before and after surgery yielded further insight into the pathophysiology of oncogenic osteomalacia. " 08/01/1980 - "Vitamin D metabolite levels in oncogenic osteomalacia." 05/01/1999 - "Tumor-induced osteomalacia is vitamin-D-resistant and often reversed by complete removal of the tumor. " 10/01/1983 - "The mechanism of this oncogenic osteomalacia is uncertain, but it may result from a tumor-induced alteration in vitamin-D metabolism or from a direct phosphaturic action of a tumor product. " 01/01/1999 - "Oncogenic osteomalacia, or rickets, is an unusual clinicopathologic entity in which vitamin D-resistant osteomalacia, or rickets, occurs in association with some tumors of soft tissue or bone. "
4.	Proteins (Proteins, Gene)FDA Link 05/01/2004 - "Expression of dentin matrix protein 1 in tumors causing oncogenic osteomalacia." 02/01/2003 - "Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia." 01/01/2021 - "Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by protein fibroblast-growth-factor-23 (FGF-23) secreting tumors. " 10/06/2010 - "Tumour-induced (or oncogenic) osteomalacia is a paraneoplastic syndrome characterised by progressive fatigue, muscle weakness, bone pain, non-healing and recurrent fractures caused by mesenchymal tumours that secrete proteins that inhibit renal phosphate transport and 1α-hydroxylation of 25-OH-vitamin D. " 08/01/2012 - "Oncogenic osteomalacia (OO) is a rare paraneoplastic condition in which a bone or soft tissue tumor induces biochemical and clinical signs and symptoms of osteomalacia (or rickets) most often by the production of the phosphaturic protein, fibroblast growth factor-23. "
5.	Phosphorus (Red Phosphorus)IBA 12/01/2019 - "The lack of treatment response and the low phosphorus were clues that eventually led to a diagnosis of tumor-induced osteomalacia. " 10/01/2007 - "Tumor-induced osteomalacia: the importance of measuring serum phosphorus levels." 01/01/2000 - "X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) are diseases that have in common abnormal proximal renal tubular function resulting in increased renal clearance of inorganic phosphorus and hypophosphatemia. " 01/01/2013 - "Oncogenic osteomalacia is a rare paraneoplastic syndrome of systemic bone demineralization secondary to a tumor-induced dysregulation of phosphorus metabolism. " 06/01/2017 - "Octreotide can be used as an adjunctive therapy to increase phosphorus levels in patients with tumor-induced osteomalacia. "
6.	Sodium-Phosphate Cotransporter Proteins (Sodium-Phosphate Cotransporter)IBA 08/01/2007 - "Original reports published in 2006/2007 bring valuable pieces of information that enable better understanding of the physiological regulation of phosphate homeostasis by more precisely defining the interplay between PHEX, vitamin D, and phosphatonins; identification of new genes causing hypophosphatemic rickets, aside from PHEX and fgf23, namely the genes encoding for a renal sodium-phosphate cotransporter, NaPiIIc, and for a bone matrix protein, DmpI; and improved diagnosis of tumor-induced osteomalacia with more precise imaging techniques for tumor localization and more precise fibroblast growth factor 23 assays. "
7.	Bone Cements (Bone Glue)IBA 01/01/2020 - "Successful and effective treatment of oncogenic osteomalacia with bone cement."
8.	dimyristoylphosphatidylinositolIBA 08/01/2007 - "Original reports published in 2006/2007 bring valuable pieces of information that enable better understanding of the physiological regulation of phosphate homeostasis by more precisely defining the interplay between PHEX, vitamin D, and phosphatonins; identification of new genes causing hypophosphatemic rickets, aside from PHEX and fgf23, namely the genes encoding for a renal sodium-phosphate cotransporter, NaPiIIc, and for a bone matrix protein, DmpI; and improved diagnosis of tumor-induced osteomalacia with more precise imaging techniques for tumor localization and more precise fibroblast growth factor 23 assays. "
9.	Hormones (Hormone)IBA 06/09/1994 - "Tumor-induced osteomalacia--unveiling a new hormone." 03/01/1999 - "The presence of a novel Pi-regulating hormone called 'phosphatonin' has been postulated in studies of the mechanisms of X-linked hypophosphatemic rickets and oncogenic osteomalacia. " 12/01/1997 - "These hypotheses do not fully explain all the available data and it remains possible that hormone(s) with little or no role in X-linked hypophosphataemic rickets may be responsible for oncogenic osteomalacia." 10/01/2018 - "Oncogenic osteomalacia is a very rare disease usually caused by a phosphaturic mesenchymal tumor, particularly the "mixed connective tissue type", secreting FGF-23 hormone. " 02/01/2021 - "Tumor-induced osteomalacia (TIO) is a rare cause of impaired bone mineralization mediated by the osteocyte-derived, phosphaturic hormone: fibroblast growth factor 23 (FGF23). "
10.	burosumabIBA 01/01/2021 - "Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia." 01/01/2020 - "Trials are ongoing to assess the utility of burosumab in the treatment of tumor-induced osteomalacia." 11/01/2023 - "Burosumab Improves Patient-Reported Outcomes in Adults With Tumor-Induced Osteomalacia: Mixed-Methods Analysis." 01/01/2023 - "Reply to: appropriate dosing of burosumab in tumor-induced osteomalacia." 01/01/2023 - "Appropriate dosing of burosumab in tumor-induced osteomalacia."

Therapies and Procedures

1.	Cryosurgery 02/01/2017 - "Although the first-line treatment for phosphaturic mesenchymal tumor-induced osteomalacia is wide surgical excision, CT-guided cryoablation widens the array of treatment options, especially in those patients who decline surgery or who are otherwise poor surgical candidates." 11/01/2017 - "Multimodality Image-Guided Cryoablation for Inoperable Tumor-Induced Osteomalacia." 02/01/2017 - "We report the case of a 25-year-old male patient with tumor-induced osteomalacia from a 1.8-cm phosphaturic mesenchymal tumor in the right distal thigh, who was treated at our institution with a single session of CT-guided cryoablation in December 2015, which resulted in biochemical and clinical resolution. " 02/01/2017 - "Successful CT guided cryoablation of phosphaturic mesenchymal tumor in the soft tissues causing tumor-induced osteomalacia: a case report." 09/01/2016 - "Ga-68 DOTATOC PET/CT-Guided Biopsy and Cryoablation with Autoradiography of Biopsy Specimen for Treatment of Tumor-Induced Osteomalacia."
2.	Drug Therapy (Chemotherapy) 01/01/1999 - "We report the first case of oncogenic osteomalacia that improved with chemotherapy, discuss this paraneoplastic syndrome, and review the medical literature regarding its etiology." 06/01/2019 - "Systemic chemotherapy and maintenance endocrine treatment along with phosphate and calcium supplementation reduced the activity of oncogenic osteomalacia and resolved the electrolytic imbalances. "
3.	Radiofrequency Ablation 07/01/2019 - "Successful Management Of Tumor-Induced Osteomalacia with Radiofrequency Ablation: A Case Series." 09/01/2014 - "Radiofrequency ablation, an effective modality of treatment in tumor-induced osteomalacia: a case series of three patients." 10/01/2012 - "We found one prior case of image-guided ablation using radiofrequency ablation for tumor-induced osteomalacia. " 07/26/2007 - "Radiofrequency ablation of a tumor causing oncogenic osteomalacia." 04/01/2017 - "The aim of this study was to evaluate the role of 68Ga-DOTANOC positron emission tomography (PET)/CT scan in localization of culprit lesion for biopsy and required intervention [surgical excision/radiofrequency ablation (RFA)] in patients with long-standing oncogenic osteomalacia (OOM)/tumour-induced osteomalacia. "
4.	Therapeutics 08/01/2014 - "[Anti-FGF23 antibody therapy for patients with tumor-induced osteomalacia]." 01/01/2011 - "Emphasis should be placed on the diagnosis and therapy of tumor induced osteomalacia." 01/01/1998 - "Oncogenic osteomalacia: clinical presentation, densitometric findings, and response to therapy." 12/01/2021 - "Complete resection of responsible tumors is the first-line therapy for patients with tumor-induced osteomalacia. " 01/01/2021 - "Successful Treatment of Tumor-Induced Osteomalacia by Multidisciplinary Therapy with Radiation to Intracranial Fibromyxoid Tumor."
5.	Radiotherapy 09/24/2021 - "Radiotherapy for a rare phosphaturic mesenchymal tumor in the middle ear presenting with oncogenic osteomalacia: A case report." 11/01/2013 - "Successful treatment of tumor-induced osteomalacia due to an intracranial tumor by fractionated stereotactic radiotherapy." 01/01/2022 - "We present the case of a 65-year-old male with tumor-induced osteomalacia (TIO) caused by an FGF23-secreting phosphaturic tumor of C2 treated definitively with stereotactic body radiation therapy (SBRT) and kyphoplasty. "